We’re excited to share another major milestone in our clinical investigation with Laprixa: patient enrolment has now begun. This moment represents years of innovation, diligent development, and collaborative effort being brought to life in a real clinical setting.
Since receiving approval from the METC and MUMC+ board, the team has been working closely with clinicians and our partners Medanco B.V. and AIM B.V. to prepare for this step.
With strong pre-clinical outcomes already behind us, seeing Laprixa move into further clinical application is an incredibly proud moment. These enrolled patients mark the beginning of an exciting new chapter as we evaluate Laprixa’s real-world clinical value.
A huge thank-you to everyone involved: from our engineering and clinical partners to the surgical teams making this investigation possible.
As part of the OP-Zuid grant, co-financed by the European Union.
Follow us for further updates as we continue our clinical study!
#MedicalDevices #Innovation #ClinicalTrials #SurgicalInnovation #MedTech #Laprixa #MinimallyInvasiveSurgery
